Dr Detlev Boison
Having a passion for translational research and for finding cures for intractable conditions that cause human suffrage and death, I seek to translate fundamental mechanisms of biochemistry and energy homeostasis into novel therapeutic approaches for the treatment of neurological and psychiatric conditions and cancer. A major research effort is the development of therapies that restore the equilibrium of adenosine and associated epigenetic changes and thereby reset the ‘disease clock’.
I graduated at the University of Köln, Germany, in 1994 with a PhD in Biochemistry. In 1995 I started my independent research career at the University and Federal Institute of Technology in Zürich where I received the venia legendi in Cellular Pharmacology in 2005 for my work on cell-based adenosine augmentation therapies for epilepsy. That same year I joined Legacy Health in Portland, Oregon, where I am currently Chair and Director of the Robert Stone Dow Neurobiology Laboratories, Co-Director of the Wayne D. Kuni & Joan E. Kuni Cancer Research Laboratory, and Director of Basic and Translational Research of the Legacy Research Institute. In addition, I hold faculty appointments at Oregon Health and Science University and at Washington State University.
I have published over 140 papers with an h-index of 46 and have delivered over 120 lectures in more than 20 different countries.
